Related Experiment Video
Updated: Jun 29, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
VKORC1 polymorphisms and complete resistance to vitamin K antagonists: About two cases
Ilham Benyamna1,2, Houda El Fissi2, Fadoua Bouzid2,3
1Department of Cardiology and Internal Medicine, Inezgane Provincial Hospital, Agadir, Morocco.
Abstract:
Complete resistance to vitamin K antagonists is a rare but serious condition. It can complicate therapeutic management, especially when direct oral anticoagulants cannot be used. Some single mutations in the VKORC1 gene have been identified in patients partially or completely resistant to vitamin K antagonists. We report the cases of two women in their fifties who presented an unexplained peripheral venous thrombosis. The aetiological assessment did not show any abnormalities. Genetic testing showed that both patients had the VKORC1 5417 GG genotype. The VKORC1 3673 genotype was GG in case 1 and GA in case 2. The two patients showed complete resistance to vitamin K antagonists which required a change in treatment with favourable outcomes. Our goal is to offer optimal care guided by a literature review.
Insights
Complete resistance to vitamin K antagonists, a rare condition, can be linked to specific VKORC1 gene mutations. Identifying these genetic factors is crucial for effective therapeutic management in affected patients.
Area of Science:
- Genetics
- Pharmacology
- Hematology
Background:
- Vitamin K antagonists (VKAs) are crucial anticoagulants.
- Complete resistance to VKAs is rare but poses significant therapeutic challenges.
- Direct oral anticoagulants may not always be suitable alternatives.
Observation:
- Two middle-aged women presented with unexplained peripheral venous thrombosis.
- Standard etiological assessments revealed no abnormalities.
- Genetic testing identified specific VKORC1 gene genotypes in both patients.
Findings:
- Both patients exhibited complete resistance to vitamin K antagonists.
- The VKORC1 5417 GG genotype was present in both cases.
- VKORC1 3673 genotypes were GG (case 1) and GA (case 2).
Implications:
- Genetic identification of VKORC1 variants is key for diagnosing VKA resistance.
- Altered treatment strategies are necessary for patients with VKA resistance.
- Understanding these genetic factors can guide optimal patient care and management.
More Related Videos
11:33Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes
Published on: March 12, 2013
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Single Nucleotide Polymorphisms-SNPs
Determination of Michaelis Constant and Maximum Elimination Rate
These parameters can be estimated by analyzing plasma concentration data post-drug administration. A notable example of this application is phenytoin, a drug with capacity-limited kinetics. It's recommended that phenytoin should be administered at two...
Treatment Resistant Cancers
Comparing Copy Number Variations and SNPs
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...